{
    "medicine_id": "d96a56c90e7d3bdb2c352ed921ea77876a37a3da",
    "platform_id": "DB05688",
    "metadata": {
        "name": "Stelara 5 mg Solution",
        "composition": "5 mg CRx 119",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in periodontal disease and rheumatoid arthritis",
            "contraindications": {
                "disease": "CRx 119 was generally well tolerated and there were no drug related serious adverse events reported The most common adverse event observed with CRx 119 was drowsiness a known side effect of amoxapine",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "CRx 119 is a novel orally available syncretic drug candidate in clinical development for immunoinflammatory diseases A syncretic drug comprises two compounds that are designed to act together synergistically through multiple pathways to provide a novel therapeutic effect which neither component alone can achieve CRx 119 contains a low dose of the steroid prednisolone and amoxapine The target product profile for CRx 119 is to selectively amplify certain elements of prednisolone s anti inflammatory and immunomodulatory effects without replicating steroid toxicity",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}